CA2045358A1 - Preparation pharmaceutique a liberation prolongee - Google Patents

Preparation pharmaceutique a liberation prolongee

Info

Publication number
CA2045358A1
CA2045358A1 CA2045358A CA2045358A CA2045358A1 CA 2045358 A1 CA2045358 A1 CA 2045358A1 CA 2045358 A CA2045358 A CA 2045358A CA 2045358 A CA2045358 A CA 2045358A CA 2045358 A1 CA2045358 A1 CA 2045358A1
Authority
CA
Canada
Prior art keywords
controlled release
pharmaceutical preparation
release pharmaceutical
water
medicinal compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2045358A
Other languages
English (en)
Other versions
CA2045358C (fr
Inventor
Kazuo Noda
Masao Kobayashi
Takashi Osawa
Shigeyuki Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26494375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2045358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CA2045358A1 publication Critical patent/CA2045358A1/fr
Application granted granted Critical
Publication of CA2045358C publication Critical patent/CA2045358C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Surgical Instruments (AREA)
  • Stringed Musical Instruments (AREA)
  • Pens And Brushes (AREA)
CA002045358A 1990-06-28 1991-06-25 Preparation pharmaceutique a liberation prolongee Expired - Lifetime CA2045358C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17176290 1990-06-28
JP171762/1990 1990-06-28
SG4995A SG4995G (en) 1990-06-28 1995-01-13 Controlled release pharmaceutical preparation

Publications (2)

Publication Number Publication Date
CA2045358A1 true CA2045358A1 (fr) 1991-12-29
CA2045358C CA2045358C (fr) 1998-04-28

Family

ID=26494375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002045358A Expired - Lifetime CA2045358C (fr) 1990-06-28 1991-06-25 Preparation pharmaceutique a liberation prolongee

Country Status (17)

Country Link
US (1) US5137733A (fr)
EP (1) EP0463877B2 (fr)
JP (1) JP2558396B2 (fr)
KR (1) KR0133511B1 (fr)
CN (1) CN1040061C (fr)
AT (1) ATE106241T1 (fr)
CA (1) CA2045358C (fr)
DE (1) DE69102211T3 (fr)
DK (1) DK0463877T3 (fr)
ES (1) ES2055962T5 (fr)
FI (1) FI103476B1 (fr)
GR (1) GR3024471T3 (fr)
HK (1) HK33895A (fr)
HU (1) HU214590B (fr)
IE (1) IE64629B1 (fr)
IL (1) IL98611A (fr)
SG (1) SG4995G (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
CN1053808C (zh) * 1993-04-24 2000-06-28 章修纲 尼非地平控释剂型
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6306438B1 (en) 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
WO1999040942A1 (fr) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a liberation controlee
FR2778848B1 (fr) * 1998-05-20 2001-11-23 Prographarm Lab Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
AU3071300A (en) * 1999-01-21 2000-08-07 Elan Corporation, Plc Multiparticulate bisoprolol formulation
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
DK1242055T3 (da) * 1999-12-23 2008-07-21 Pfizer Prod Inc Hydrogelstyret doseringsform til lægemidler
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6984402B2 (en) 2000-10-03 2006-01-10 Elite Laboratories, Inc. Chrono delivery formulations and method of treating atrial fibrillation
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7125561B2 (en) * 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
CA2518806C (fr) * 2003-03-11 2012-05-01 Seikagaku Corporation Composition polysaccharide photoreticulee et procede de fabrication
SI1631251T1 (sl) 2003-04-24 2011-10-28 Jagotec Ag Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
EP1759719B1 (fr) * 2004-05-07 2015-01-07 Seikagaku Corporation Matière de remplissage de nucleus pulposus
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (fr) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
EP1830648A4 (fr) * 2004-12-09 2008-03-12 Celgene Corp Traitement au moyen de d-threo methylphenidate
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
JP2008024708A (ja) * 2007-08-20 2008-02-07 Euro-Celtique Sa アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
US20100272762A1 (en) * 2009-04-22 2010-10-28 Dr. Suwelack Skin & Health Care Ag Freeze-Dried Coated Molded Article
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
ES2640968T3 (es) * 2010-12-03 2017-11-07 Nippon Soda Co., Ltd. Forma de dosificación sólida que contiene una HIDROXIALQUIL CELULOSA de baja viscosidad
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
WO2012129551A1 (fr) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Procédés et compositions destinés au traitement du trouble déficitaire de l'attention
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
JP5146859B2 (ja) * 2011-07-11 2013-02-20 ユーロ−セルティーク エス．エイ． アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
CA3018328A1 (fr) 2014-10-31 2016-04-30 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944311A (ja) * 1982-09-07 1984-03-12 Santen Pharmaceut Co Ltd 徐放性顆粒およびその製造法
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4559225A (en) * 1984-02-16 1985-12-17 Fourman Robert G Sunscreen composition
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
DE59000232D1 (de) * 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法

Also Published As

Publication number Publication date
GR3024471T3 (en) 1997-11-28
CN1040061C (zh) 1998-10-07
HU214590B (hu) 1998-04-28
DK0463877T3 (da) 1994-06-27
JP2558396B2 (ja) 1996-11-27
CN1058533A (zh) 1992-02-12
DE69102211T3 (de) 1997-08-28
IE64629B1 (en) 1995-08-23
ES2055962T3 (es) 1994-09-01
IE912166A1 (en) 1992-01-01
DE69102211T2 (de) 1994-09-15
KR920000313A (ko) 1992-01-29
KR0133511B1 (ko) 1998-04-23
FI912952A0 (fi) 1991-06-18
FI912952L (fi) 1991-12-29
HUT59321A (en) 1992-05-28
EP0463877B2 (fr) 1997-07-02
SG4995G (en) 1995-06-16
IL98611A0 (en) 1992-07-15
HK33895A (en) 1995-03-17
AU7924391A (en) 1992-01-02
AU634400B2 (en) 1993-02-18
FI103476B (fi) 1999-07-15
US5137733A (en) 1992-08-11
EP0463877B1 (fr) 1994-06-01
IL98611A (en) 1998-10-30
ATE106241T1 (de) 1994-06-15
DE69102211D1 (de) 1994-07-07
EP0463877A1 (fr) 1992-01-02
FI103476B1 (fi) 1999-07-15
CA2045358C (fr) 1998-04-28
ES2055962T5 (es) 1997-09-16
HU912170D0 (en) 1991-12-30
JPH04235123A (ja) 1992-08-24

Similar Documents

Publication Publication Date Title
IL98611A0 (en) Controlled release pharmaceutical preparation
AU576891B2 (en) Biphasic release tablet with drug in polymercoat and drug in the core
CA2304110A1 (fr) Comprime de theophylline a liberation prolongee
CA2175122A1 (fr) Systeme therapeutique transdermique a liberation prolongee
CA2033277A1 (fr) Preparation pharmaceutique a liberation controlee et procede de fabrication de ladite preparation
EP0213083A3 (fr) Comprimé à libération contrôlée
CA2306333A1 (fr) Formulation multiparticulaire de morphine orale
IE883810L (en) Sustained release pharmaceutical compositions
EP0351760A3 (fr) Additif alimentaire destiné aus ruminants
CA2044398A1 (fr) Forme galenique pharmaceutique orale solide a liberation programmee
CA2038245A1 (fr) Micropellets utiles en pharmacologie
CA2181502A1 (fr) Preparation pharmaceutique sous forme de capsule enrobee, liberee dans la partie inferieure du tube digestif
AU2037092A (en) Fabric care composition comprising water soluble or water dispersible copolymer containing uv-absorbing monomer
AU4927090A (en) Medicaments having controlled release of the active compound
CA2121038A1 (fr) Preparation orale pour liberation dans le tractus gastro-intestinal inferieur
CA2000932A1 (fr) Forme pharmaceutique orale multiparticulaire a liberation controlee
CA2041044A1 (fr) Formule orale de series polypeptidiques dissociatives pour le gros intestin
AU7191891A (en) Water soluble salts of purpuromycin and pharmaceutical formulations thereof
CA2124425A1 (fr) Comprimes pharmaceutiques liberant la substance active apres une periode de temps definie
EP0712873A3 (fr) Résines acryliques hydrophiliques et composition de revêtement aqueuse les contenant
IL100529A0 (en) Chiral polymers,their preparation and their application in the preparation of optically active 2-arylpropionic acids
ITRM910522A1 (it) Procedimento per la preparazione di un preparato cosmetico e/o farmaceutico in forma di pellicola spugnosa idrosolubile, e pellicola spugnosa idrosolubile cosi' ottenibile
IT1255058B (it) Compresse farmaceutiche a rilascio della sostanza attiva dopo un intervallo di tempo programmabile

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20110625